Background: Cysteinyl leukotriene (CysLT) is one of the proinflammatory mediators released by the bronchi during inflammation. CysLTs exert their biological effects via specific G-protein-coupled receptors. CysLT 1 receptor antagonists are available for clinical use for the treatment of asthma. Recently, crosstalk between CysLT 1 and P2Y 6 receptors has been delineated. P2Y receptors are expressed in apical and/or basolateral membranes of virtually all polarized epithelia to control the transport of fluid and electrolytes. Previous research suggests that CysLT 1 receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. However, the detailed molecular mechanism underlying the inhibition remains unresolved.
Introduction
Bronchial asthma is an inflammatory disease that affects millions of people worldwide. Among the proinflammatory mediators released by the bronchi are cysteinyl leukotrienes (CysLTs). They are lipid mediators derived from arachidonic acid by the 5-lipoxygenase (5-LO) pathway [1] and play critical roles in the pathogenesis of asthma [2, 3] . CysLTs exert their biological effects via specific G-protein-coupled receptors. To date, there are two cloned human CysLT receptor subtypes, namely CysLT 1 and CysLT 2 [4] . Specific CysLT 1 receptor antagonists, such as montelukast, pranlukast, and zafirlukast, are available for clinical use for the treatment of asthma [5] . Recently, crosstalk between CysLT 1 receptor and P2Y 6 receptor signaling systems has been reported in human mast cells [6] and monocyte/macrophage-like cells [7] . P2Y 6 is a member of the P2Y receptor family that is expressed in the apical and/or basolateral membranes of virtually all polarized epithelia to control the transport of fluid and electrolytes [8, 9] . It has been shown that uridine diphosphate (UDP), a selective agonist for the P2Y 6 receptor, can also activate the CysLT 1 receptor. On the other hand, CysLT 1 receptor antagonists could inhibit the effects of the extracellular nucleotide acting at P2Y receptors [10] . Evidence also suggests that CysLTs and UDP do not share the same receptor and the CysLT 1 receptor possesses dual CysLT/UDP specificity.
In the airway, chloride (Cl 2 ) secretion and sodium (Na + ) reabsorption can be modulated by the activation of multiple P2Y receptors that couple to the phospholipase C (PLC) and calciumsignaling pathway. Recently, work from this laboratory has confirmed that a human bronchial epithelial cell line, 16HBE14o-, expresses multiple P2Y receptors mRNA and proteins, including the P2Y 6 receptor [11] . UDP could stimulate both calcium (Ca 2+ )-and 39,59-cyclic monophosphate (cAMP)-dependent chloride ion secretion in 16HBE14o-cells. An increase in cAMP production could in turn activate both protein kinase A (PKA) and an exchange protein directly activated by cAMP (Epac) [12] . As there is little knowledge regarding the effects of specific CysLT 1 receptor antagonists on airway epithelial transport, the aim of this project was to examine their effects on P2Y 6 receptor-mediated Cl 2 secretion in a human bronchial epithelial cell line (16HBE14o-) and to investigate the possible signal transduction pathway(s) through which the antagonists may act.
Results

Expression of CysLT 1 and P2Y 6 receptors in the 16HBE14o-cell monolayer
To examine the presence of CysLT 1 and P2Y 6 receptors in 16HBE14o-cells, western blot analysis was conducted. The protein expression of CysLT 1 and P2Y 6 receptors in 16HBE14o-cells was detected as shown in Fig. 1 . The CysLT 1 receptor polyclonal antibody identified an intense 44-kDa band in whole cell lysates of 16HBE14o-cell monolayers (Fig. 1A , left lane). The specificity of the band was confirmed by the complete abolishment of the immunoreactive signal in 16HBE4o-cells by the CysLT 1 receptor polyclonal antibody that had been preadsorbed with specific blocking peptides. The blocking peptides correspond to amino acid residues 318-337 of the human CysLT 1 receptor (Fig. 1A , right lane). On the other hand, the P2Y 6 receptor was identified as an intense 41-kDa band (Fig. 1B, left lane) . The specificity of the band was confirmed by the complete abolishment of the immunoreactive signal by the P2Y 6 receptor antibody preadsorbed with specific blocking peptides. The blocking peptides correspond to amino acid residues 322-343 of the human P2Y 6 receptor (Fig. 1B, right lane) . Western blot analysis demonstrated that 16HBE14o-cells expressed CysLT 1 receptors and confirmed our previous finding on P2Y 6 receptor expression in this cell line [11] .
Activation of the P2Y 6 but not the CysLT 1 receptor stimulated increases in I SC and [Ca 2+ ] i in 16HBE14o-cells UDP is the specific agonist of the P2Y 6 receptor [13, 14] , which has been shown to regulate ion transport processes in airway epithelial cells via both Ca 2+ -and cAMP-dependent pathways [11] . First, the effect of apical application of UDP on I SC was investigated using a conventional Ussing chamber study. Fig. 2A shows the representative recordings of I SC in response to the apical application of 30-300 mM UDP. The addition of UDP to the apical side rapidly increased I SC . The I SC change consisted of biphasic responses, namely an initial transient peak (first peak) and a second increase within 2 min (second peak). In another series of experiments, the intracellular calcium concentration was measured in 16HBE14o-cells grown on glass coverslips by using a fluorescent technique. Fig. 2B shows the representative recordings of [Ca 2+ ] i in response to 30-300 mM UDP application. The changes in [Ca 2+ ] i were obtained by measuring the maximal increase of the 340/380 nm fluorescence ratio upon stimulation. Fig. 2C and 2D summarize the change of I SC (DI SC ) and fluorescence ratio (Dratio) induced by UDP application, respectively. Apical application of UDP elicited a concentrationdependent increase in the first peak of I SC , with a UDP concentration of 100 mM eliciting the maximal increase in I SC . The increase in the second peak of I SC also exhibited a concentration-dependent relationship with the apical application of UDP, again with 100 mM UDP eliciting the maximal increase in I SC . The addition of basolateral UDP evoked only a small and variable increase in I SC in both phases (data not shown). Due to the small response of basolateral UDP-induced I SC , only I SC induced by apical addition of UDP was investigated further. The increase in [Ca 2+ ] i upon the addition of UDP also exhibited concentration dependency, again with 100 mM UDP inducing the largest increase in [Ca 2+ ] i . In our previous study, the UDP-induced [Ca 2+ ] i increase was abolished and the increase in I SC response was greatly attenuated when the cells were treated with BAPTA-AM, an intracellular Ca 2+ chelator. The results therefore confirmed our previous findings that UDP could stimulate a calcium-dependent I SC in 16HBE14o-cells [11] .
Although CysLT 1 receptor protein was expressed in 16HBE14o-cells, activation of the receptor by its agonists, CysLT C 4 (LTC 4 ) or LTD 4 [15] , did not stimulate any discernible increase in [Ca 2+ ] i and had no effect on the subsequent increase in Fura-2 ratio induced by UDP (UDP alone: 0.06060.004; +LTC 4 : 0.04960.005; +LTD 4 : 0.05260.004, p.0.05). As shown in Fig. 2E , the presence of LTC 4 or LTD 4 
CysLT 1 receptor antagonists inhibited UDP-evoked I SC
The functional relationships between the CysLT and P2Y receptors have been highlighted in several recent reports. For example, it has been shown that CysLT 1 receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors in U937 cells [10] . Therefore, the effect of three commonly used CysLT 1 antagonists (montelukast, pranlukast, and zafirlukast) on P2Y 6 receptor-coupled I SC was measured in 16HBE14o-cells. The epithelia were pretreated with various concentrations (0.3-3 mM) of CysLT 1 antagonists at the apical side, followed by apical application of 100 mM UDP. Addition of montelukast, pranlukast or zafirlukast (up to 3 mM) alone did not stimulate any increase in I SC . Fig. 3A shows the representative recordings of I SC in response to the application of 100 mM UDP in the absence (control) or presence of montelukast (1 mM). Fig. 3B summarizes the changes of the first and second peaks of I SC in response to the application of 100 mM UDP after apical pretreatment with montelukast. In the presence of apical montelukast (0.7, 1, and 3 mM), the UDPinduced first peak was significantly reduced. The second peak of I SC was not affected by montelukast.
Similar responses were obtained when the epithelia were stimulated with UDP in the presence of pranlukast (Fig. 3C) or zafirlukast (Fig. 3E) . The UDP-induced first I SC peak was significantly inhibited by apical pretreatment of the epithelia with 1 and 3 mM pranlukast (Fig. 3D) or zafirlukast (Fig. 3F) . Again, the UDP-induced second I SC peak was not inhibited by the apical application of pranlukast or zafirlukast. For the highest concentration of CysLT 1 receptor antagonists tested (3 mM), approximately 50% of the UDP-evoked first peak of I SC was inhibited. All three CysLT 1 receptor antagonists failed to inhibit the apical UDP-evoked I SC (first and second peaks) when applied to the basolateral aspect of the epithelia (data not shown). Similar experiments were conducted using a P2Y 2 /P2Y 4 ] i evoked by UDP is caused by the coupling of P2Y 6 receptors to PLC and hence the production of the inositol trisphosphate (IP 3 ) [13] . To test the effect of montelukast on P2Y 6 receptor-dependent calcium signaling, two pharmacological agents, U73122 and xestospongin C (XeC), were used. U73122 is a specific inhibitor of PLC [16] , whereas XeC is a novel blocker of the IP 3 receptor [17] . In the experiment, the cells were perfused with normal K-H solution containing 2.5 mM Ca ] i increase. The data suggest that montelukast may interfere with the signaling pathway at a level upstream of the IP 3 -induced Ca 2+ release. To investigate whether montelukast may act upstream of the IP 3 -induced Ca 2+ release, the epithelia were coincubated with both U73122 (0.1 mM) and montelukast (1 mM). Similarly, the data demonstrated that coincubation of the epithelia with both U73122 and montelukast reduced the UDP-induced [Ca 2+ ] i response to 63.262.6% of the control response, which is not statistically different from that in the presence of U73122 alone (n = 5, p.0.05). Taken together, the data suggest that montelukast may interfere with the calcium-signaling pathway at a level upstream of PLC activity and the production of IP 3 . -and cAMPdependent Cl 2 secretion across airway epithelial cells [11, 18, 19] , possibly by increasing cellular cAMP production [11, 20] . Increases in cAMP production could in turn activate two downstream signaling molecules, PKA and exchange protein directly activated by cAMP (Epac) [12] , which could then regulate epithelial Cl Forskolin and 8-Br-cAMP are general cAMP level elevators that cannot distinguish between their two downstream targets, PKA and Epac. Therefore, in the second series of experiments, specific Epac or PKA activator were used. 8-CPT-29-O-Me-cAMP and Sp-6-Phe-cAMPs were thus employed to potentiate the UDPinduced I SC . 8-CPT-29-O-Me-cAMP is a specific activator of Epac [22] that potentiated the first peak of I SC to 140.367.2% (+8-CPT-29-O-Me-cAMP: 24.5461.26 mA/cm 2 , p,0.05, n = 4-6), but the second peak was not significantly potentiated. Sp-6-Phe-cAMP is a potent PKA activator. However, it does not activate Epac and thus can serve as an Epac negative control [23, 24] . Sp-6-Phe-cAMP potentiated the first peak of I SC but not the second peak. The first peak of I SC was increased to 128.166.6% of the control response (+Sp-6-Phe-cAMP: 22.4261.15 mA/cm 2 , p,0.05, n = 4-6). To test the inhibitory effect of different CysLT 1 antagonists, montelukast, pranlukast, or zafirlukast (1 mM) were added together with various potentiators (1 mM) 10 min prior to the addition of UDP (100 mM). As summarized in Fig. 5F , the UDP-evoked I SC (first peak) in the presence of cAMP elevating agents (forskolin and 8-Br-cAMP), Epac 
CysLT 1 antagonists inhibited the UDP-evoked Cl
Pranlukast, but not montelukast or zafirlukast, inhibited the activation of Epac
To examine whether the inhibitory action of pranlukast occurs through Epac, we monitored Epac1 activation by using a cyan fluorescent protein (CFP)-Epac-yellow fluorescent protein (YFP) fusion construct, which has been used by others to detect real-time changes in [cAMP] via a fluorescence resonance energy transfer (FRET)-based approach [25] [26] [27] . Fig. 6A shows that 16HBE14o-cells were successfully transfected with the fusion construct of CYP-Epac-YFP, which is sensitive to the dynamic changes of [cAMP] . As expected, the Epac activator 8-CPT-29-O-cAMP (50 mM) evoked about a 20% increase in the CFP/FRET emission ratio, which indicates a global increase in cAMP (Fig. 6B and C) . Pranlukast could inhibit the activation of Epac mediated by 8-CPT-29-O-cAMP. Fig. 6D summarizes the inhibitory effects of montelukast, pranlukast, and zafirlukast. In the presence of pranlukast (1 mM), the increase in the CFP/FRET emission ratio induced by 8-CPT-29-O-cAMP was reduced to 45.5% of the control (p,0.05, n = 8). Montelukast (1 mM) and zafirlukast (1 mM) exhibited no inhibitory effects (p.0.05, n = 8-10). In the control experiments, addition of montelukast, pranlukast or zafirlukast (1 mM) did not induce any discernible increase in FRET ratio (n = 3).
Zafirlukast, but not montelukast or pranlukast, inhibited UDP-activated PKA activity
The cAMP-dependent pathway underlying the inhibitory effects of montelukast, pranlukast, and zafirlukast on UDP was also studied by a PKA activity assay. PKA activity in 16HBE14o-cells was measured by a PKA assay that measures the phosphorylation of Kemptide, a synthetic substrate specific for PKA. The PKA activity was measured as a function of fluorescence intensity. As shown in Fig. 6E , phosphorylated peptides migrated towards the positively charged anode. The application of 100 mM UDP for 5 min significantly increased PKA activity by 150.0620.2% when compared with that in untreated cells. The UDP-induced PKA activity was suppressed after pretreatment with zafirlukast (1 mM) to 82.0615.1% (p,0.05, n = 4), whereas montelukast (1 mM) and pranlukast (1 mM) did not significantly inhibit UDP-induced PKA activity. Summarized data are shown in Fig. 6F . Addition of montelukast, pranlukast, zafirlukast, LTC 4 or LTD 4 (1 mM) did not significantly affect the PKA activity of the 16HBE14o-cells when compared with untreated control (one-way ANOVA, n = 3, p.0.05).
Expression of Epac in 16HBE14o-cells
As our data suggest pranlukast inhibited the activation of Epac, we further studied the distribution of endogenous Epac 1 and Epac 2 in 16HBE14o-cells by immunostaining (Fig. 7) . Epac 1 staining (red) of 16HBE14o-cells was mostly localized to the cytoplasm of 16HBE14o-cells. The signal intensity of Epac 1 was stronger than that of Epac 2, which may suggest a higher and more uniform expression of Epac 1 in these cells. In the control experiment, omission of the primary antibodies resulted in a complete loss of the immunofluorescence.
Discussion
Crosstalk between CysLT 1 receptor and P2Y 6 
receptors
In the airway, Cl 2 secretion and Na + reabsorption can be modulated by the activation of multiple P2Y receptors. The coordinated regulation of Cl 2 secretion and Na + reabsorption is necessary to maintain the thickness and composition of airway surface liquid, which in turn affects airway mucus clearance [28] . We have demonstrated previously that 16HBE14o-cells express multiple P2Y receptors, including P2Y 1 , P2Y 2 , P2Y 4 , and P2Y 6 . When activated by UDP, P2Y 6 receptors are coupled to Ca 2+ -and cAMP-dependent pathways, thereby leading to transepithelial Cl 2 secretion [11] . Recently, it was discovered that crosstalk exists between P2Y 6 and CysLT 1 receptors [6, 29] . CysLT 1 is the receptor of CysLTs, which are key mediators of airway inflammatory disorders. Both P2Y and CysLT 1 receptors belong to the superfamily of G protein-coupled receptors (GPCRs), and previous studies have suggested functional and structural similarities between these two receptors [30] . CysLT 1 receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors in monocyte-macrophage-like cell lines [10] . CysLT 1 receptor antagonists inhibit UDP-but not carbachol-induced [Ca 2+ ] i increases, suggesting that the antagonists specifically Figure 7 . Immunolocalization of Epac 1 and Epac 2 in 16HBE14o-cells. With the use of specific antibodies, immunofluorescence staining of Epac 1 (A) and Epac 2 (C) were localized to the cytoplasm of 16HBE14o-cells, as indicated by the red colour. Under the conditions specified in the Methods section, the signal intensity of Epac 1 was stronger than that of Epac 2, which may suggest a higher and more uniform expression of Epac 1 in these cells. In the negative control (E), omission of the primary antibodies resulted in a complete loss of the immunofluorescence. The corresponding images taken in brightfield were shown in B, D and F. doi:10.1371/journal.pone.0022363.g007 interact with the P2Y receptor signaling pathway. However, the detailed molecular mechanism underlying the inhibition remains unresolved. More importantly, whether similar inhibitory effects could be observed in human airway epithelia remains unknown. In the present study, the effects of three specific CysLT 1 antagonists on P2Y 6 receptor-mediated signaling pathways and ion transport in human bronchial epithelial 16HBE14o-cells were examined.
In this study, the protein expression of P2Y 6 [30] . In cells that express both types of receptors, the addition of LTD 4 and UDP caused a robust increase in [Ca 2+ ] i [7] , and LTC 4 could cross-desensitize UDP receptors [6] . In addition, 16HBE14o-cells possess an active biosynthetic pathway for the production of leukotrienes, such as LTC 4 [32] . Profita et al. have shown that 16HBE14o-cells expressed functional CysLT 1 receptors that coupled to the STAT-1 signaling pathway. The authors, however, had to enhance the expression of CysLT 1 receptor by transfecting the cells with a construct encoding the receptor to circumvent the low and variable receptor expression in the cells [33] . Therefore, the fact that no CysLT 1 receptor-mediated [Ca 2+ ] i response was observed in this study may be related to the low-level expression of the receptor, or the receptor may be coupled less efficiently to G q/11 protein. Moreover, the CysLT 1 receptor agonists (LTC 4 and LTD 4 ) and antagonists (montelukast, pranlukast and zafirlukast) at 1 mM had no effect on either FRET ratio or PKA activity. These data further suggest that 16HBE14o-cells do not possess functional CysLT 1 receptors. However, we could not exclude the possibility that the CysLT 1 receptor may still couple to other cellular signaling pathways without interfering with the P2Y 6 receptor -mediated Ca 2+ and I SC responses.
CysLT 1 antagonists inhibited UDP-induced I SC
To examine whether the CysLT 1 antagonists would have any effect on P2Y 6 receptor-mediated ion transport processes, the effects of three commonly used CysLT 1 antagonists, montelukast, pranlukast, and zafirlukast, on UDP-induced I SC were examined. They are potent and selective CysLT 1 receptor antagonists marketed for the treatment of asthma [34] and are sold under the trade names of Singulair, Ultair, and Accolate, respectively [35] . The cells were pretreated with CysLT 1 antagonists 10 min before addition of UDP. In general, all three CysLT 1 antagonists inhibited the first peak of UDP-induced I SC , with montelukast inhibiting the peak at a lower concentration than that of pranlukast and zafirlukast. However, the second I SC peak was not influenced by these antagonists. Therefore, all three CysLT 1 receptor antagonists, when applied to the apical but not basolateral side of the epithelia, are capable of inhibiting the transient but not the sustained component of the I SC , resulting in the inhibition of Cl 2 secretion across the airway epithelia.
Montelukast inhibited UDP-induced [Ca 2+ ] i
Recently, we have demonstrated that P2Y 6 receptors couple to both cAMP-and Ca 2+ -dependent pathways in 16HBE14o-cells [11] . For the Ca 2+ -dependent pathway, upon the coupling of UDP to P2Y 6 ] i increase induced by UDP. Therefore, montelukast is likely to interfere with the pathway at a level upstream of PLC activity and the production of IP 3 , probably at the receptor level. It has been proposed that the functional inhibition of nucleotide-elicited effects by leukotriene antagonists was mediated through direct allosteric interaction with the P2Y receptor [10] , which is phylogentically related to CysLT receptors [36] . However, the detailed molecular interaction remains unknown and requires further investigation. Another possibility is that the CysLT 1 antagonists exerted their inhibitory effects via an as yet unidentified signaling mechanism common to P2Y 6 receptors, but not characteristic of other P2Y receptor subtypes.
Pranlukast and Zafirlukast inhibited UDP-induced I SC via different mechanisms
Airway epithelial Cl 2 secretion is stimulated by two important cytosolic second messengers, [Ca 2+ ] i and cAMP, and the latter could also potentiate Ca 2+ -mediated Cl 2 secretion in intestinal T84 cells [37] . PKA and Epac are two downstream targets of cAMP that transduce diverse cellular actions [12, 38] . In intestinal epithelial cells, cAMP/PKA may potentiate Cl 2 secretion by phosphorylating apical cystic fibrosis transmembrane conductance regulator (CFTR) Cl 2 channels. Other potential targets include basolaterally located Na + /2Cl 2 /K + cotransporters or cAMPdependent K + channels [39] . The effect of Epac on epithelial Cl 2 secretion or ion channel activity is less well understood. A recent study suggested that Epac could regulate intestinal Cl 2 secretion via a PKA-independent mechanism by stimulating the PLC/IP 3 -mediated calcium signaling pathway in intestinal epithelial T84 cells [21] . However, we were not able to detect any increase in [Ca 2+ ] i induced by Epac activators (Ko et al., unpublished data). The addition of forskolin also could not stimulate any increase in [Ca 2+ ] i in 16HBE14o-cells [11] . In this study, we investigated whether the three CysLT 1 receptor antagonists interfered with the potentiating effects of cAMP and Epac on UDP-mediated Cl 2 secretion. Cells were treated with drugs activating the adenylate cyclase-cAMP-PKA/Epac signaling cascade at different levels. Firstly, two general cAMP level elevators, forskolin and 8-BrcAMP, were used. Forskolin is an adenylyl cyclase activator, while 8-Br-cAMP is a cAMP analog; therefore, both could increase the intracellular level of cAMP. The first and second peaks of the I SC response were potentiated by forskolin and 8-Br-cAMP. Our data demonstrated that pranlukast and zafirlukast inhibited the first peak of the UDP-induced I SC potentiated by forskolin or 8-BrcAMP. However, montelukast did not inhibit the first peak of potentiated I SC . On the other hand, the second peak of the potentiated I SC was not inhibited any of the three CysLT 1 antagonists. The data demonstrated that the the UDP-evoked Cl 2 secretion potentiated by the presence of various cAMP elevating agents was inhibited by pranlukast and zafirlukast but not montelukast.
As mentioned above, cAMP has two downstream targets, PKA and Epac, which cannot be distinguished by general cAMP level elevators. Thus, 8-CPT-29-O-Me-cAMP, a specific activator of Epac [22] , was used to investigate the effect of CysLT 1 antagonists on Epac-potentiated I SC induced by UDP. 8-CPT-29-O-Me-cAMP potentiated the first peak but not the second peak of the UDPinduced I SC . The 8-CPT-29-O-Me-cAMP-potentiated first peak of UDP-induced I SC was inhibited only by pranlukast. It appears that pranlukast could reduce the I SC response potentiated through the action of Epac. There are two possibilities for the inhibitory mechanism. Pranlukast may inhibit the UDP-induced I SC through inhibition of cAMP production or Epac activation. However, it is unlikely that pranlukast inhibits the production of cAMP because pranlukast also inhibited the UDP-induced I SC potentiated by the general cAMP analog 8-Br-cAMP. To confirm that pranlukast reduces the I SC response by acting through Epac, FRET was employed. In the study, we used a FRET-based cAMP indicator, CFP-Epac-YFP. 8-CPT-29-O-Me-cAMP activated Epac, which caused a significant increase in the FRET emission ratio. In the presence of pranlukast, the increase in the FRET emission ratio elicited by 8-CPT-29-O-Me-cAMP was reduced, indicating that pranlukast inhibited the activation of Epac. These data further confirms that pranlukast reduces UDP-evoked responses by acting through the action of Epac, which is expressed in 16HBE14o-cells as shown by immunocytochemistry. The expression of Epac 1 but not Epac 2 in 16HBE14o-cells is consistent with the observation that Epac 1 mRNA is expressed ubiquitously, whereas Epac 2 mRNA is predominately expressed in the brain and endocrine tissues [40] .
On the other hand, Sp-6-Phe-cAMP served as an Epac-negative control because it activates PKA but not Epac [23, 24] . Sp-6-PhecAMP also potentiated the first peak but not the second peak of UDP-induced I SC . The UDP-induced I SC first peak potentiated by Sp-6-cAMP was inhibited by zafirlukast, but not by montelukast or pranlukast. The cAMP-dependent PKA pathway underlying the effects of montelukast, pranlukast, and zafirlukast on UDP was further studied by a PKA activity assay. The data showed that UDP-induced PKA activity was suppressed only in the presence of zafirlukast, confirming that zafirlukast could reduce the I SC response acting through the action of PKA. Taken together, these findings imply that montelukast, pranlukast, and zafirlukast differentially inhibited the second messenger-mediated changes in I SC induced by the apical application of UDP. In particular, pranlukast could inhibit the cAMP-dependent pathway potentiated through the action of Epac, while zafirlukast may inhibit the same pathway potentiated through PKA. Montelukast, however, does not interfere with the cAMP-dependent pathway. However, we could not exclude the possibility that the CysLT 1 antagonists may have direct effects on apical Cl 2 channels, which await further investigation.
P2Y 6 receptors and inflammatory response
Aside from regulation of ion transport in various epithelia, P2Y receptors, including P2Y 6 , have been implicated as important players in the initiation, amplification, and spread of acute inflammation as well as the downregulation of chronic inflammation [41, 42] . Recently, it was shown for the first time that P2Y 6 receptors modulate the release of the chemokines CCL20 and IL-8 from human nasal epithelial cells and thereby could alter immune cell recruitment in airways [43] . The specific agonist for P2Y 6 receptors, UDP, stimulates the production of proinflammatory cytokines in retinal pigment epithelial cells [44] and monocytic cells [45] . In an ulcerative colitis mouse model, both P2Y 2 and P2Y 6 receptor mRNA and protein expression was upregulated in the inflammatory response of intestinal epithelial cells. Stimulation of the intestinal epithelial cells with the P2Y 6 receptor agonist UDP resulted in an increased expression and release of IL-8 [46] . Montelukast, pranlukast, and zafirlukast are now widely used clinically for the treatment of asthma and allergic rhinitis. Our data suggest that they may act through a mechanism of action that is independent of CysLT 1 receptor antagonism. Therefore, it is possible that part of the antiinflammatory effect of CysLT 1 receptor antagonists in asthma is mediated through the P2Y 6 -mediated signaling pathway, hence ameliorating the proinflammatory responses. In airway epithelia, it is important to maintain the volume or height of the liquid (air surface liquid, ASL) that lines the surface of airway epithelia. Enhancing fluid and electrolyte transport may improve airway surface hydration and improve mucus clearance, which is hypersecreted in various respiratory diseases, such as asthma. Stimulation of various P2Y receptors, including P2Y 6 receptors, will increase Cl 2 secretion into the lumen of the airway, which subsequently drives water secretion due to the high water permeability of the airway epithelia.Therefore, the inhibition of P2Y 6 receptor-mediated Cl 2 secretion may have the opposite effect by reducing the hydration of the airway surface, which therefore compromises the innate immunity of the airway epithelia.
In summary, our data demonstrate that the three specific CysLT 1 receptor antagonists have different pharmacological actions against the P2Y 6 receptor-mediated signaling pathway in 16HBE14o-cells. Although all antagonists inhibited the UDPevoked I SC increase, only montelukast inhibited Ca 2+ signaling, while pranlukast and zafirlukast inhibited the potentiation effect of cAMP signaling mediated by Epac and PKA, respectively. The data showed that these three specific CysLT 1 receptor antagonists are not as highly specific as previously thought, and this may provide implications for the clinical use of these compounds in asthma or other inflammatory conditions. Therefore, further studies should be undertaken to evaluate the efficiency and underlying cellular mechanisms of the therapeutic rationale. With respect to this study, the detailed mechanisms of CysLT 1 antagonists on inflammation-related P2Y receptors should be further investigated to uncover the crossregulatory mechanisms between CysLT 1 and P2Y receptors, and more importantly, the impact on airway epithelial transport.
Materials and Methods
Cell Culture
All experiments were performed using the immortalized cell line 16HBE14o-, which was derived from bronchial surface epithelial cells [47] . Standard culture techniques were used as described previously [11, 48] . In brief, cells were maintained in Minimum Essential Medium with Earle's salt supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) L-glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin. Cells were cultured on plastic flasks coated with fibronectin and collagen (BD Biosciences, San Jose, CA) and were incubated in humidified 95% air-5% CO 2 at 37uC.
Western Blot
Cells grown in culture flasks were lysed in radioimmunoprecipitation assay buffer [1% NP-40, 0.1% sodium dodecyl sulfate, 0.5% deoxycholic acid, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl] supplemented with protease inhibitors [5 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 2 mM b-glycerolphosphate, 1 mM ethylene glycol tetraacetic acid, 1 mM ethylenediaminetetraacetic acid]. The cell lysate was collected, and the supernatant was harvested after centrifugation at 20,0006g for 20 min at 4uC. The total protein content in each sample was determined using the Bradford assay (Bio-Rad, Hercules, CA). Forty micrograms of protein were used for western blotting and separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis. Separated proteins were electroblotted to a polyvinylidene fluoride membrane (Immobilon-P, Millipore Corporation, Billerica, MA) by using a wet transfer system (BioRad). Membranes were blocked for 1 h at room temperature by using 1% bovine serum albumin in phosphate buffered saline containing 0.05% Tween 20 and incubated overnight at 4uC with specific CysLT 1 receptor polyclonal antibody (1:300, rabbit polyclonal anti-CysLT 1 , no. 120500, Cayman Chemical, Ann Arbor, MI) or P2Y 6 receptor antibody (1:200, no. APR-011, rabbit polyclonal anti-P2Y 6 , Alomone, Jerusalem, Israel). The positions of positive bands were detected by incubation with horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (Dako, Glostrup, Denmark) and visualized using an enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ). Their apparent molecular masses were calculated based on prestained sodium dodecyl sulfate polyacrylamide gel electrophoresis low-range protein standards (Bio-Rad).
Immunocytochemistry 16HBE14o-cells cultured on 12-mm glass coverslips were rinsed twice with phosphate-buffered saline (PBS) and then fixed in a 4% (w/v) paraformaldehyde solution for 30 min at 4uC. Cells were permabilized with 0.5% Triton X-100 in PBS for 15 min and blocked with 10% fetal calf serum (FCS) in PBS for 30 min at room temperature. Cells were then incubated overnight at 4uC with Epac 1 or Epac 2 rabbit polyclonal antibodies (Abcam: ab21236 or ab21238) at a dilution of 1:200 in the blocking solution (10% FCS in PBS). At the end of primary antibody incubation, cells were washed three times in PBS and then incubated with goat anti-rabbit IgG (H+L) coupled to Alexa FluorH 568 (Invitrogen: A11011) at 1:400 dilution in PBS for 15 min. After rinsing off the excess fluorescent dye-labeled secondary antibody, the coverslip was mounted on a microscopic slide using Shandon ImmuMount TM (Thermo Scientific) and visualized with a Zeiss Axioskop 2 plus microscope under fluorescent microscopy and brightfield. Control staining was performed following the above procedure and differed only in the omission of the primary antibodies.
Measurement of short-circuit current (I SC )
Confluent 16HBE14o-cells were used to measure I SC as described previously [37] . The monolayers were cultured on Transwell-COL membranes (Costar, Cambridge, MA) with a 0.4-mm pore diameter (culture area 0.2 cm 2 ), mounted in an Ussing chamber, and bathed in normal Krebs-Henseleit (K-H) solution. To generate a favorable gradient for Cl 2 exit, a basolateral-toapical Cl 2 gradient was applied across the monolayers by changing the apical K-H solution to one with a reduced Cl 2 concentration [47] . The potential difference was clamped to 0 mV, and I SC was simultaneously measured using a voltage-clamp amplifier (VCC MC6; Physiologic Instruments, San Diego, CA). A transepithelial potential difference of 1 mVs was applied periodically, and the resultant change in the current was used to calculate the transepithelial resistance using Ohm's law. Cells reached confluence after 10 days with a resistance greater than 150 V?cm 
Measurement of PKA activity
Confluent 16HBE14o-cells grown on 6-well plates were incubated with vehicle alone or UDP in the presence or absence of different CysLT 1 receptor antagonists for 5 min. The PKA activity was assayed using the PepTagH non-radioactive cAMPdependent protein kinase assay system (Promega, Madison, WI) as described previously [37] . The phosphorylated and nonphosphorylated samples were separated on a 0.8% agarose gel at 100 V for 15 min. The gel was photographed, and the fluorescence intensity was quantified by the FluorChem TM 8000 imaging system.
Measurement of intracellular calcium concentration ([Ca
2+ ] i )
Calcium signals in cells grown on glass coverslips were measured as previously described [11, 49] . Briefly, cells were loaded with Fura-2 by incubation (45 min, 37uC) in K-H solution containing 3 mM Fura-2-AM and 1.6 mM pluronic F127. The Fura-2 loaded cells were washed with K-H solution, and the entire coverslip was then transferred to a closed perfusion chamber mounted on an inverted microscope (Olympus IX70, Center Valley, PA) equipped with a 620 water immersion objective (numerical aperture 0.6). The excitation light source was provided by a multi-wavelength illuminator (Polychrome IV, TILL Photonics, GmBH, Hilden, Germany) that enables rapid interchange between two excitation wavelengths (340 and 380 nm). The emitted fluorescence was passed through a 400-nm dichroic mirror, filtered at 510 nm, and then collected using a digital cooled CCD camera (Quantix, Photometrics, Tucson, AZ). Images were digitized and analyzed using MetaFluor Imaging Software (v.7.5, Molecular Devices, Downingtown, PA). Fura-2 ratios were used to represent changes in [Ca 2+ ] i .
Real-time monitoring of cAMP by FRET
Real-time cAMP changes in living cells were monitored using CFP-Epac-YPF, an Epac-based polypeptide FRET reporter [27] . FRET imaging experiments were performed using the MetaFluor Imaging System (with FRET module) similar to that described above. 16HBE14o-cells were transfected with the Epac-based cAMP sensor. Cells on glass coverslips were placed on the inverted microscope and excited at 436 nm. CFP and YFP images were simultaneously recorded by the imaging setup equipped with the Photometrics DV 2 emission splitting system (Photometrics, Tucson, AZ) including two emission filters (470/30 nm for CFP and 535/30 m for FRET). Acquired fluorescence images were background subtracted, and real-time cAMP changes were represented by normalized CFP/FRET emission ratio similar to that described by Li et al. [50] .
Materials and solutions
The bicarbonate-buffered K-H solution contained the following components (in mM): NaCl, 117; NaHCO 3 , 25; KCl, 4.7; MgSO 4 , 1.2; KH 2 PO 4 , 1.2; CaCl 2 , 2.5; and D-glucose, 11; its pH was 7.4 when bubbled with 5% CO 2 /95% O 2 . The nominally Ca 2+ -free solution was prepared by omitting Ca 2+ from the above solution. The low Cl 2 solution (10 mM) was prepared by isosmotically replacing NaCl, KCl, CaCl 2 , and MgCl 2 with Nagluconate, K-gluconate, Ca-gluconate, and Mg-sulfate, respectively. The membrane-permeant acetoxymethylester (AM) forms of Fura-2 and pluronic F127 were obtained from Molecular Probes (Eugene, OR). UDP, forskolin, and 8-Br-cAMP were obtained from Sigma-Aldrich (St. Louis, MO, USA). Before the use of UDP, this nucleotide (10 mM) was incubated (1 h at 37uC) in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-buffered saline containing hexokinase (10 IU/ml, Boehringer, Mannheim, Germany) and 22 mM D-glucose to remove contaminating nucleotide triphosphates. The resulting solution was then aliquoted and stored at 220uC. Montelukast, pranlukast, and zafirlukast were purchased from Cayman Chemical. 8-CPT-29-O-Me-cAMP and Sp-6-Phe-cAMP were obtained from BIOLOG (Bremen, Germany). All other general laboratory reagents were obtained from Sigma-Aldrich, and all cell culture reagents were obtained from Invitrogen (Carlsbad, CA, USA).
Data analysis
Pooled data are presented as means 6 standard errors (S.E.), and values of n refer to the number of experiments in each group. Experimentally induced changes (D) in the Fura-2 fluorescence ratio and I SC were quantified by measuring each parameter at the peak of a response and subtracting the equivalent values measured immediately prior to stimulation. Statistical comparisons between original data before normalization were performed using one-way analysis of variance with Bonferroni post-hoc test, with a p,0.05 considered significant.
